2017 - CIRTA


This page contains exclusive content for the member of the following sections: TTS, ITA. Log in to view.

10- Intestinal Transplantation

52.15 - Teduglutide as Rescue Therapy for Chronic Graft Dysfunction in Intestinal Transplantation

Presenter: Jennifer, Garcia, Miami, United States
Authors: Jennifer Garcia, Jennifer Jebrock, Allyson Lipp, Gennaro Selvaggi, Akin Tekin, Ji Fan, Seigo Nishida, Rodrigo Vianna, Thiago Beduschi

Teduglutide as Rescue Therapy for Chronic Graft Dysfunction in Intestinal Transplantation

Jennifer Garcia1, Jennifer Jebrock1, Allyson Lipp1, Gennaro Selvaggi1, Akin Tekin1, Ji Fan1, Seigo Nishida1, Rodrigo Vianna1, Thiago Beduschi1.

1Miami Transplant Institute, University of Miami/ Jackson Memorial Hospital, Miami, FL, United States

Introduction: Long term graft dysfunction requiring parenteral support has been frequently described post intestinal transplant. Diarrhea, dehydration and weight loss are the most common symptoms. Chronic rejection may be the cause, but diagnosis is very difficult to make. Teduglutide is a glucagon-like peptide 2 analogue that restores intestinalfunctional integrity by promoting growth of the mucosa, increasing fluid and nutrient absorption and slowing the transit.  It is commonly used for patients with short bowel syndrome.

Methods: To describe our first experience with the use of teduglutide for the treatment of chronic graft dysfunction after intestinal transplantation. This report, to the best of our knowledge, is the first time teduglutide is ever used in an intestinal transplant recipient. 

Results: A 68 years old female, 5 years post intestinal transplant due to volvulus, presented with symptoms of graft dysfunction. Diarrhea, dehydration, renal failure and weight loss led to frequent admissions. Extensive worked up was performed. No signs of acute cellular rejection or infections were identified. Bacterial overgrowth was ruled out. Pancreatic exocrine function was normal. Patient did not have any donor specific antibody.  Multiple attempts to control the symptoms (anti-diarrheal medications, binding agents, pancreatic enzymes, different diets) had failed. Patient was eventfully discharged on parenteral hydration (2 liters /day). Episodes of line infection became routine. Patient satisfaction was very low due to social limitation. Around 10 episodes of diarrhea limited daily activities.  Teduglutide was started daily after colonoscopy ruled out presence of polyps. Improvement of the graft function was immediately observed with decrease of the evacuations from 10 to 1 to 2 a day with formed stools. Other anti-diarrheal medications were stopped. Hydration was weaned over 3 months due to initial poor patient intake and line was removed. Creatinine and BUN returned to the baseline with improvement of the GFR. Pre-albumin normalized. Interestingly, IgG levels which were initially noted to be low, increased to normal levels likely due to resolution of protein enteropathy. Citrulline levels more than doubled. Minor edema in the legs was observed in the first month of treatment. Surveillance with colonoscopy performed every 6 months without any abnormal findings. Patient remains free of any parenteral support 18 months after treatment commence.
 
Discussion: High patient satisfaction and great improvement in quality of life is associated with resolution of the previous symptoms. Risk of the development of polyps outweigh the many hurdles of parenteral support. Teduglutide may become a therapeutic option on the treatment of intestinal failure not only pre but also post transplant.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada